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Letters to the Editor
Oral contraceptive (OC) use and risk of breast cancer
Sir
In a recent issue of your journal a paper by Tryggvadottir et al
(TTG) (1997) was published. The paper is based on a study that is
a replication of one that we have already reported [T6masson and
Tomasson, 1996 (TT)] using the same databases. The differences
between these two studies are that their observation period is 6
years longer than ours, that they controlled for age at menarche
while we controlled for family history of breast cancer and that
TTG used the information from the first visit to the screening
clinic, which might lead to misclassification bias - although they
state that adding information from a later visit does not affect the
results - whereas TT used information from the last visit.
TTG do not mention our study, which however was known to
them, and therefore fail to discuss the difference between the find-
ings reported in the two papers. Our results suggested that use of
oral contraception (OC) decreases the risk of breast cancer being
diagnosed before the age of45 years, whereas it does not decrease
the risk for the age group 45-54 years (a non-significant increase
ofrisk). The duration ofOC use did not seem to affect the risk. We
found no significant two-way interactions within the group diag-
nosed with cancer before the age of45 years. According to Table 2
in the paper by TTG, the odds ratio (OR) is 2.2 for breast cancer if
exposure to OC is more than 4 years compared with exposure to
OC less than 4 years for the cohort 1953-1967 but 1.1 for the
cohort 1945-1967, thus suggesting an interaction between cohort
and use ofOC. The presentation ofthe interaction in Table 2 is not
standard, and the statistical significance and functional form of it
is unclear. Later in the text, TTG mention a significant interaction
term (P = 0.04). A footnote ofTable 2 in TTG states that the esti-
mates in the table are corrected for the confounding variables.
However, the OR derived directly from the figures given in the
table seem to give similar results. Using these same figures, it can
be calculated that the OR for the cohort 1945-1952 is about 0.66,
yet a substantial part (75%) ofthe cases belong to that cohort.
As the incidence of breast cancer increases sharply with age,
and if the results of Table 2 are interpreted literally as a pure age
effect, the conclusion to be drawn is that OC use increases the risk
for young women in whom the total risk is low but decreases the
risk for older women in whom the total risk is much higher. It is
therefore quite compatible with TTG that OC use would decrease
overall incidence ofbreast cancer before the age of50 years.
Assuming that earlier brands of OC are equally 'dangerous' as
modern ones, it is possible to approximate the odds ratio (OR*)
due to OC use at young ages. According to a survey cited in 1TG,
72% ofthe later cohorts (1951-1967) and about 31% ofthe earlier
cohorts (1945-1950) stated that they had used OC before the age
of20. Assuming that OR* is the odds ratio forextended OC use (>
4 years) started before the age of20 years, and OR is the odds ratio
for extended OC use started after the age of 20 years, then the
numbers in TTG can be expressed by the following equations:
0.31 OR* + 0.69 OR = 0.8 (1)
0.72 OR* + 0.28 OR = 2.0 (2)
Equations 1 and 2 represent the cohorts 1945-1950 and
1951-1967, respectively, and the numbers 0.8 and 2.0 are the
weighted average (averaged over early and late starters) odds
ratios shown in Table 3 in TTG. With 0.8 and 2.0 on the right-hand
side, there is no solution when both OR and OR* are positive. If
0.8 in equation 1 was replaced with 1 we would get the solution
,OR = 0.24 and OR* = 2.68, i.e. a protection due to extended OC
use when started after the age of 20 years and maybe a 10-fold
(2.68/0.24) risk for early starters vs late starters. A ratio of that
order is bound to have shown up in larger studies. These calcula-
tions are of course only approximations, but the message is that if
there is a cohort effect as a result of different patterns in starting
OC use, it is clear that the numbers on the right-hand side ofequa-
tions 1 and 2 have to be much closer to 1 to get sensible results, i.e.
there is little leeway for an eventual cohort difference on the basis
ofage difference when starting OC use.
In summary, these two Icelandic studies agree with the
Collaborative Group on Hormonal Factors in Breast Cancer
(1996) that the use of OC has very little impact on the risk for
breast cancer. It could be that the odds ratio is greater than 1 for
women who start using OC at a young age, but it seems to be very
close to 1. The results of TT and TTG are compatible with results
of the Collaborative Group (1996) that OC use does not have
much impact, in either direction, on the cumulative incidence of
breast cancer. A possible factor is that later cohorts might be
diagnosed earlier in life. A confounding factor that is difficult to
control for is that the women who start OC early might be subject
to more medical evaluation, which is compatible with the
Collaborative group (1996) who found that early OC users have a
more benign form ofcancer when diagnosed.
H Tomasson,
University ofIceland,
Oddi vi Sturlugotu,
IS-101 Reykjavik,
Iceland
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